Ask AI
ProCE Banner Activity

Best Practices in Resistant Hypertension: From Complexity to Control

Clinical Thought

Take home best practices for diagnosing and managing patients with resistant hypertension according to the 2025 AHA/ACC High Blood Pressure Guideline, including the latest on new and emerging therapies, to better help patients achieve blood pressure control.

Released: November 24, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca Pharmaceuticals.

AstraZeneca Pharmaceuticals

Target Audience

This educational program is intended for physicians, NPs, and PAs in cardiology who care for patients with resistant hypertension or uncontrolled blood pressure.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in an effort to optimize the care of patients with resistant hypertension or uncontrolled blood pressure.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify true resistant HTN and the clinical implications of delayed recognition or suboptimal management

  • Discuss the scientific and clinical basis for novel therapies targeting different pathophysiological pathways as a strategy to improve blood pressure control

  • Develop evidence-based, personalized treatment plans that integrate the potential clinical utility of novel agents to address unmet needs and advance the management of resistant HTN

Faculty Disclosure

Primary Author

Wanpen Vongpatanasin, MD, FACC, FAHA: consultant/advisor/speaker: AstraZeneca.